Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Venture Eyes Ophthalmology--And Likes What It Sees

This article was originally published in Start Up

Executive Summary

Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.
Advertisement

Related Content

PanOptica Takes $30MM Series A Round, Licenses Ophthalmic Drug From Astellas
Alcon Shareholders Reject "Inadequate" Novartis Offer
AAO Highlights: Back (of the Eye) to the Future
Financings Of The Fortnight: Despite Venture Capital Fundraising Struggles, Deals Continue
Lux Bioscience Brings In $50 Million To Take Luveniq To The Finish Line Alone
Sirion Therapeutics Inc.
Ophthotech Corp.
Abbott buys AMO, Gets Double-Digit Growth Segment
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Potentia Pharmaceuticals Inc.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel